DFTX

Equity

Definium Therapeutics, Inc.

Health Care · Biotechnology

$17.45

+17.45 (+0.00%)

Open

N/A

Day Range

$16.81 - $17.96

52W Range

$4.70 - $18.70

Volume

2M

Price History

Key Statistics

Market Cap

N/A

P/E Ratio

N/A

EPS

N/A

Dividend Yield

N/A

P/B Ratio

N/A

Payout Ratio

N/A

ROE

N/A

Debt/Equity

N/A

Latest News

Definium (DFTX) Q4 2025 Earnings Call Transcript

Motley Fool 8 hours ago

Definium Therapeutics Inc (DFTX) Q4 2025 Earnings Call Highlights: Strong Financial Position ...

GuruFocus.com 20 hours ago

Definium Therapeutics Q4 Earnings Call Highlights

MarketBeat 21 hours ago

Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates

Business Wire 1 day ago

Definium Therapeutics to Participate at Upcoming Investor Conferences

Business Wire 3 days ago

Peers in Health Care

Symbol Name Price Mkt Cap Div Yield Change
CRSP CRISPR Therapeutics AG $60.14 N/A - +0.00%
AHCO AdaptHealth Corp. $9.15 N/A - +0.00%
ABBV AbbVie Inc. $232.08 N/A 2.87% +0.00%
ABCL AbCellera Biologics Inc. $3.61 N/A - +0.00%
ABT Abbott Laboratories $116.35 N/A 2.06% +0.00%
ATAI AtaiBeckley Inc. $3.63 N/A - +0.00%
NVO Novo Nordisk A/S $37.45 N/A 4.49% +0.00%
001540.KQ AHN-GOOK PHA $8,070.00 N/A 5.45% +0.00%

Community Sentiment

Sign in to vote

0% Bullish 0% Neutral 100% Bearish

0 votes

Discussion (0)

Sign in to join the discussion

Loading comments...

About Definium Therapeutics, Inc.

Definium Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

definiumtx.com →

Dividend Safety

Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.

50

Borderline

Based on 4 fundamental factors

Analysis Tools

Sign in for analysis tools

Share